Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263638 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4TSHRLOX | |
| SCHEMBL6609352 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4TSHRLOX | |
| SCHEMBL15412364 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4TSHRLOX | |
| SCHEMBL1727052 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4TSHRLOX | |
| SCHEMBL193470 | 0.85 | — | — | |
| SCHEMBL27623257 | 0.82 | — | — | |
| SCHEMBL2974544 | 0.82 | TSHR (0.46) | CYP3A4TSHR | |
| SCHEMBL28176269 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TDP1CYP3A4TSHRLOX | |
| SCHEMBL11064559 | 0.78 | — | — | |
| SCHEMBL1727261 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TDP1CYP3A4TSHRLOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114394-B1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | claimed |
| US-7777060-B2 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | claimed |
| EP-2114394-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008100301-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | claimed |
| EP-2114394-B1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-7777060-B2 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2114394-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008100301-A1 | PLATINUM ANALOGS WITH BIS-NITRILE-CONTAINING LIGANDS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | BIONUMERIK PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194680-A1 | Platinum analogs with bis-nitrile-containing ligands | PCNA, LIG4, TOP2B | ALDH1A1 2084/4885TDP1 1028/4885CYP3A4 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.